Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2020

View Archived Issues

Engineered brown fat cells improve blood sugar control

For organs, rejuvenation helps transplantation

Cartesian initiates first-in-human study of Descartes-30 in patients with ARDS and COVID-19

REPAVID-19 study of reparixin in severe COVID-19 pneumonia approved in Brasil

Aligos Therapeutics divulges new antivirals

DE Shaw Research patents Abeta aggregation inhibitors

Researchers from Czech Republic present compounds for neurodegeneration

LNP-023 demonstrates efficacy, both as add-on and monotherapy, in patients with PNH

Agios Pharmaceuticals identifies PKM2 and PKLR activators

Starpharma creates long-acting, water-soluble version of remdesivir

PTC Therapeutics discovers new compounds targeting mRNA splicing machinery

Janssen discontinues development of pimodivir for influenza A

CanSino announces start of phase III trial with Ad5-nCoV vaccine for COVID-19

New therapeutic target for blood sugar control identified

Transmembrane domain-deficient STING protein developed for cGAMP delivery

BIAL presents phase I data on the dopamine beta-hydroxylase inhibitor zamicastat

Nocion begins healthy volunteer study of NOC-100 for cough

Health Canada clears initiation of phase III trial of Pulmonem's reformulated dapsone for COVID-19

First-in-human data presented for TQA-3526

Abivax reports 2-year data from phase IIa maintenance study of ABX-464 in ulcerative colitis

HMPL-453 enters phase II study for advanced intrahepatic cholangiocarcinoma

New phase I/II trial evaluates Treadwell's CFI-402411 in solid tumors

Sanofi and GSK advance adjuvanted COVID-19 vaccine into phase I/II evaluation

Enesi partners with University of Adelaide to develop thermostable solid dose DNA Zika vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...